Payment overview · 2025
General Payments
$617.01
30 reported records · 9 companies
Healthcare provider profile · identity verified
Jamal Isber, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LA FOLLETTE, TN · NPI 1912936808
Verified facts
What the public records show
CMS Open Payments records show Jamal Isber, M.D. received $617.01 in general payments during 2025 across 30 reported records.
Regeneron Healthcare Solutions, Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 403 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $115.23 | 18.7% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $91.46 | 14.8% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $90.61 | 14.7% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $78.99 | 12.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.48 | 12.7% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $57.99 | 9.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.35 | 6.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.59 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.31 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.02 | 29 |
| Education | $78.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $284.83 | 13 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $91.46 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.48 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $57.99 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.59 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 403 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
403 | 101 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 682 | 221 |
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 125 |
| Gabapentin | Gabapentin | 411 | 75 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 403 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 94 |
| Lorazepam | Lorazepam | 282 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 237 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 69 |
| Montelukast Sodium | Montelukast Sodium | 226 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 64 |
| Furosemide | Furosemide | 191 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 191 | 47 |
| Omeprazole | Omeprazole | 183 | 52 |
| Meloxicam | Meloxicam | 172 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 161 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 43 |
| Metformin Hcl | Metformin Hcl | 147 | 40 |
| Potassium Chloride | Potassium Chloride | 147 | 57 |
| Azithromycin | Azithromycin | 136 | 109 |
| Eliquis | Apixaban | 125 | 34 |
| Lisinopril | Lisinopril | 123 | 40 |
| Ozempic | Semaglutide | 122 | 23 |
| Jardiance | Empagliflozin | 116 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 104 | 40 |
| Alprazolam | Alprazolam | 101 | 12 |
| Trazodone Hcl | Trazodone Hcl | 98 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 72 |
| Allopurinol | Allopurinol | 91 | 21 |
| Losartan Potassium | Losartan Potassium | 79 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 24 |
| Clonazepam | Clonazepam | 76 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 24 |
| Ibuprofen | Ibuprofen | 74 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 21 |
| Methylprednisolone | Methylprednisolone | 68 | 57 |
| Benazepril Hcl | Benazepril Hcl | 65 | 15 |
| Donepezil Hcl | Donepezil Hcl | 63 | 16 |
| Glimepiride | Glimepiride | 62 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 60 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 16 |
| Ondansetron Odt | Ondansetron | 59 | 23 |
| Simvastatin | Simvastatin | 59 | 17 |
| Tramadol Hcl | Tramadol Hcl | 59 | 26 |
| Mirtazapine | Mirtazapine | 57 | 12 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Bumetanide | Bumetanide | 52 | 17 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Famotidine | Famotidine | 50 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 13 |
| Sertraline Hcl | Sertraline Hcl | 46 | 16 |
| Carvedilol | Carvedilol | 44 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | 13 |
| Spironolactone | Spironolactone | 42 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 25 |
| Nitroglycerin | Nitroglycerin | 39 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | 23 |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Theophylline Er | Theophylline Anhydrous | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Buspirone Hcl | Buspirone Hcl | 31 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Clonidine Hcl | Clonidine Hcl | 26 | 15 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Forteo | Teriparatide | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.01 · 30 records | Regeneron Healthcare Solutions, Inc. | AREXVY, Arikayce, DUPIXENT, INSPIRE, JARDIANCE, Ozempic, Prolastin-C Liquid, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error